Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Cash from Financing Activities (2020 - 2025)

Ovid Therapeutics' Cash from Financing Activities history spans 6 years, with the latest figure at $75.2 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities changed N/A year-over-year to $75.2 million; the TTM value through Dec 2025 reached $75.2 million, up 11991.16%, while the annual FY2025 figure was $75.2 million, 11991.16% up from the prior year.
  • Cash from Financing Activities reached $75.2 million in Q4 2025 per OVID's latest filing, up from $15000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $75.2 million in Q4 2025 to a low of -$43599.0 in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $6.0 million, with a median of $112868.5 recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: crashed 139.93% in 2022, then soared 68984.61% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $109180.0 in 2021, then crashed by 139.93% to -$43599.0 in 2022, then skyrocketed by 68984.61% to $30.0 million in 2023, then crashed by 99.87% to $38000.0 in 2024, then surged by 197739.47% to $75.2 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Cash from Financing Activities are $75.2 million (Q4 2025), $15000.0 (Q3 2025), and $13000.0 (Q1 2025).